Literature DB >> 25986886

[Neuroendocrine neoplasms of the breast].

M Anlauf1, M Neumann, S Bomberg, K Luczak, S Heikaus, C Gustmann, C Antke, S Ezziddin, C Fottner, M Pavel, U-F Pape, A Rinke, H Lahner, M Schott, B Cremer, D Hörsch, R P Baum, U Groh, I Alkatout, C Rudlowski, P Scheler, T K Zirbes, J Hoffmann, T Fehm, H E Gabbert, S E Baldus.   

Abstract

Neuroendocrine neoplasms (NEN) of the breast are specific tumor entities. According to the literature up to 5% of breast neoplasms are malignant epithelial neoplasms of the breast. They are defined by a neuroendocrine (NE) architecture and cytology combined with an expression of the neuroendocrine vesicle markers chromogranin A and/or synaptophysin. The diagnosis is supplemented by the receptor status and the proliferative activity. According to the World Health Organization (WHO) classification of 2012 the following groups of NEN are distinguished: (1) invasive breast carcinoma with NE differentiation, (2) well-differentiated neuroendocrine tumor (NET) and (3) poorly differentiated small cell carcinoma (NEC). This review article focuses on (1) the definition and basic principles of diagnostics, (2) the history, nomenclature and WHO classification from 2003 and 2012, (3) the frequency of breast NEN, (4) the hereditary background and functional activity, (5) the expression of receptors and (6) the possible clinical implications. In addition, the first results of a retrospective single center study (n = 465 patients with breast cancer over a time period of 4 years) on the frequency of NEN of the breast at the Breast Center of the University Hospital Düsseldorf are presented. In this study a frequency of 4.5% of NEN was found based on a diagnostic cut-off of > 50% Chromogranin A and/or synaptophysin positive tumor cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986886     DOI: 10.1007/s00292-015-0024-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  47 in total

1.  [ON THE CARCINOID GROWTH FORM OF THE CARCINOMA MAMMAE, ESPECIALLY THE CARCINOMA SOLIDUM (GELATINOSUM) MAMMAE].

Authors:  F FEYRTER; G HARTMANN
Journal:  Frankf Z Pathol       Date:  1963-10-03

2.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

3.  Watery diarrhoea: an unusual manifestation of breast cancer.

Authors:  N al Saudi; E Maartense; J Scherpenisse; A W F M van Leeuwen
Journal:  Neth J Med       Date:  2007-12       Impact factor: 1.422

4.  Inflammatory breast cancer with refractory diarrhea: a case report.

Authors:  Joseph Kattan; Albert Chemaly; Marwan Chemaly; Dani Jamal; Souheil Karaa; Lina Moacdieh
Journal:  J Med Liban       Date:  2011 Jul-Sep

5.  Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients.

Authors:  Y Zhang; Z Chen; Y Bao; Z Du; Q Li; Y Zhao; F Tang
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

6.  Neuroendocrine differentiated carcinomas of the breast: a distinct entity.

Authors:  Osman Zekioglu; Yíldíz Erhan; Metin Ciriş; Hatice Bayramoglu
Journal:  Breast       Date:  2003-08       Impact factor: 4.380

7.  Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours.

Authors:  F Elgeti; H Amthauer; T Denecke; I Steffen; F Heuck; L Stelter; J Ruf
Journal:  Nuklearmedizin       Date:  2008       Impact factor: 1.379

8.  Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report.

Authors:  Stefania Nicoletti; Maximilian Papi; Fabrizio Drudi; Manuela Fantini; Debora Canuti; Emiliano Tamburini; Cinzia Possenti; Enzo Pasquini; Massimo Brisigotti; Alberto Ravaioli
Journal:  J Med Case Rep       Date:  2010-06-30

9.  Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy.

Authors:  Yuliang Zhu; Qun Li; Jianming Gao; Zhenyu He; Rui Sun; Guoping Shen; Haibo Zhang; Weixiong Xia; Junjie Xu
Journal:  Breast J       Date:  2013-05-31       Impact factor: 2.431

10.  Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation.

Authors:  Giordano Savelli; Alberto Zaniboni; Francesco Bertagna; Giovanni Bosio; Lutfun Nisa; Carlo Rodella; Giorgio Biasiotto; Giovanni Bettinsoli; Elena Migliorati; Alessia Peli; Roberta Falchi; Francesca Giuffrida; Raffaele Giubbini
Journal:  Breast Care (Basel)       Date:  2012-10       Impact factor: 2.860

View more
  3 in total

1.  Primary Neuroendocrine Breast Carcinoma in a 13-Year-Old Girl: Ultrasonography and Pathology Findings.

Authors:  Mazamaesso Tchaou; Tchin Darré; Koué Folligan; Akomola Sabi; Lantam Sonhaye; Azanledji Boumé; Akila Bassowa; Solange Adani-Ifé; Gado Napo-Koura
Journal:  Case Rep Radiol       Date:  2017-09-10

2.  Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis.

Authors:  Natalia Krawczyk; Rowena Röwer; Martin Anlauf; Caja Muntanjohl; Stephan Ernst Baldus; Monika Neumann; Maggie Banys-Paluchowski; Sabine Otten; Katharina Luczak; Eugen Ruckhäberle; Svjetlana Mohrmann; Jürgen Hoffmann; Thomas Kaleta; Bernadette Jaeger; Irene Esposito; Tanja Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-11-18       Impact factor: 2.915

3.  Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review.

Authors:  Ozlem Ozdemir; Baha Zengel; Yasar Yildiz; Seray Saray; Ahmet Alacacioglu; Funda Tasli; Zuleyha Can Erdi; Utku Oflazoglu; Halil Taskaynatan; Tarik Salman; Umut Varol; Zehra Hilal Adibelli; Raika Durusoy; Yuksel Kucukzeybek
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.